BRIEF-Genmab Announces Positive Phase 3 Results For Epcoritamab Plus Lenalidomide

Genmab A/S
AbbVie, Inc.

Genmab A/S

GMAB

0.00

AbbVie, Inc.

ABBV

0.00

June 30 (Reuters) - Genmab A/S GMAB.CO:

  • ANNOUNCES POSITIVE PHASE 3 RESULTS FOR EPCORITAMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, DEMONSTRATING STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL

  • EPCORE DLBCL-4 REDUCES RISK OF PROGRESSION AND DEATH BY UP TO 60%

  • REPORTS PHASE 3 EPCORE DLBCL-4 TRIAL MEETS PRIMARY ENDPOINT IN R/R DLBCL

  • EPCORITAMAB PLUS LENALIDOMIDE SHOWS CONSISTENT SAFETY PROFILE

  • CO AND ABBVIE TO ENGAGE REGULATORY AUTHORITIES ON EPCORE DLBCL-4 RESULTS

Source text: ID:nGNX3DJgj3

Further company coverage: GMAB.CO


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.